Diagnostic value of WIF1 methylation for colorectal cancer: a meta-analysis
Metrics: PDF 1309 views | HTML 2396 views | ?
Haochang Hu1,*, Bin Li1,*, Cong Zhou1,*, Xiuru Ying1,*, Min Chen1, Tianyi Huang1, Yuehong Chen1, Huihui Ji1, Ranran Pan1, Tiangong Wang1, Danjie Jiang1, Yanfei Chen1, Yong Yang1 and Shiwei Duan1
1Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang, China
*These authors are co-first authors of this work
Shiwei Duan, email: [email protected]
Keywords: DNA methylation; colorectal cancer; WIF1; diagnostic value; meta-analysis
Received: August 09, 2017 Accepted: December 23, 2017 Published: January 03, 2018
As a common antagonist of Wnt/β-catenin signaling, Wnt inhibitory factor 1 (WIF1) plays an important role in the tumor progression. The aim of our meta-analysis was to summarize the diagnostic value of WIF1 methylation in colorectal cancer (CRC). Eligible studies were retrieved by a systemic search among PubMed, Embase, CNKI, and Wanfang literature databases. The diagnostic value of WIF1 methylation for CRC was assessed by the summary receiver operating characteristics (SROC) test. Our meta-analysis of 12 studies between 1420 CRC samples and 946 control samples showed that WIF1 hypermethylation was significantly associated with CRC (P < 0.001, OR = 30.10, 95% CI = 19.48-46.50). WIF1 hypermethylation, as a diagnostic biomarker for CRC, has a pooled sensitivity of 0.40 (95% CI: 0.37-0.42), a pooled specificity of 0.95 (95% CI: 0.93-0.96), a pooled positive-likelihood ratio (PLR) of 8.65 (95% CI, 4.47-16.73), and a pooled negative-likelihood ratio (NLR) of 0.41 (95% CI, 0.30-0.55), a diagnostic odds ratio (DOR) of 26.86 (95% CI: 15.73-45.89), and an area under the curve (AUC) of 0.9115. In conclusion, our study established that WIF1 hypermethylation might be a promising diagnostic biomarker for CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.